Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal.

Autor:	de Bruijn I; Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Kundra R; Memorial Sloan Kettering Cancer Center, New York, New York., Mastrogiacomo B; Memorial Sloan Kettering Cancer Center, New York, New York., Tran TN; Memorial Sloan Kettering Cancer Center, New York, New York., Sikina L; Dana-Farber Cancer Institute, Boston, Massachusetts., Mazor T; Dana-Farber Cancer Institute, Boston, Massachusetts., Li X; Memorial Sloan Kettering Cancer Center, New York, New York., Ochoa A; Memorial Sloan Kettering Cancer Center, New York, New York., Zhao G; Memorial Sloan Kettering Cancer Center, New York, New York., Lai B; Memorial Sloan Kettering Cancer Center, New York, New York., Abeshouse A; Memorial Sloan Kettering Cancer Center, New York, New York., Baiceanu D; The Hyve, Utrecht, the Netherlands., Ciftci E; Dana-Farber Cancer Institute, Boston, Massachusetts., Dogrusoz U; Bilkent University, Ankara, Turkey., Dufilie A; Dana-Farber Cancer Institute, Boston, Massachusetts., Erkoc Z; Dana-Farber Cancer Institute, Boston, Massachusetts., Garcia Lara E; The Hyve, Utrecht, the Netherlands., Fu Z; Dana-Farber Cancer Institute, Boston, Massachusetts., Gross B; Memorial Sloan Kettering Cancer Center, New York, New York., Haynes C; Children's Hospital of Philadelphia, Philadelphia, Pennsylvania., Heath A; Children's Hospital of Philadelphia, Philadelphia, Pennsylvania., Higgins D; Children's Hospital of Philadelphia, Philadelphia, Pennsylvania., Jagannathan P; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada., Kalletla K; Children's Hospital of Philadelphia, Philadelphia, Pennsylvania., Kumari P; Dana-Farber Cancer Institute, Boston, Massachusetts.; Caris Life Sciences, Irving, Texas., Lindsay J; Dana-Farber Cancer Institute, Boston, Massachusetts., Lisman A; Memorial Sloan Kettering Cancer Center, New York, New York., Leenknegt B; The Hyve, Utrecht, the Netherlands., Lukasse P; The Hyve, Utrecht, the Netherlands., Madela D; Memorial Sloan Kettering Cancer Center, New York, New York., Madupuri R; Memorial Sloan Kettering Cancer Center, New York, New York., van Nierop P; The Hyve, Utrecht, the Netherlands., Plantalech O; The Hyve, Utrecht, the Netherlands., Quach J; Dana-Farber Cancer Institute, Boston, Massachusetts., Resnick AC; Children's Hospital of Philadelphia, Philadelphia, Pennsylvania., Rodenburg SYA; The Hyve, Utrecht, the Netherlands., Satravada BA; Memorial Sloan Kettering Cancer Center, New York, New York., Schaeffer F; The Hyve, Utrecht, the Netherlands., Sheridan R; Memorial Sloan Kettering Cancer Center, New York, New York., Singh J; The Hyve, Utrecht, the Netherlands., Sirohi R; Dana-Farber Cancer Institute, Boston, Massachusetts., Sumer SO; Memorial Sloan Kettering Cancer Center, New York, New York., van Hagen S; The Hyve, Utrecht, the Netherlands., Wang A; Memorial Sloan Kettering Cancer Center, New York, New York., Wilson M; Memorial Sloan Kettering Cancer Center, New York, New York., Zhang H; Memorial Sloan Kettering Cancer Center, New York, New York., Zhu K; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada., Rusk N; Memorial Sloan Kettering Cancer Center, New York, New York., Brown S; Memorial Sloan Kettering Cancer Center, New York, New York., Lavery JA; Memorial Sloan Kettering Cancer Center, New York, New York., Panageas KS; Memorial Sloan Kettering Cancer Center, New York, New York., Rudolph JE; Memorial Sloan Kettering Cancer Center, New York, New York., LeNoue-Newton ML; Vanderbilt University Medical Center, Nashville, Tennessee., Warner JL; Brown University, Providence, Rhode Island., Guo X; Sage Bionetworks, Seattle, Washington., Hunter-Zinck H; Sage Bionetworks, Seattle, Washington., Yu TV; Sage Bionetworks, Seattle, Washington., Pilai S; Memorial Sloan Kettering Cancer Center, New York, New York., Nichols C; Memorial Sloan Kettering Cancer Center, New York, New York., Gardos SM; Memorial Sloan Kettering Cancer Center, New York, New York., Philip J; Memorial Sloan Kettering Cancer Center, New York, New York., Kehl KL; Dana-Farber Cancer Institute, Boston, Massachusetts., Riely GJ; Memorial Sloan Kettering Cancer Center, New York, New York., Schrag D; Memorial Sloan Kettering Cancer Center, New York, New York., Lee J; American Association for Cancer Research: Project GENIE, Philadelphia, Pennsylvania., Fiandalo MV; American Association for Cancer Research: Project GENIE, Philadelphia, Pennsylvania., Sweeney SM; American Association for Cancer Research: Project GENIE, Philadelphia, Pennsylvania., Pugh TJ; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada., Sander C; Harvard Medical School, Boston, Massachusetts., Cerami E; Dana-Farber Cancer Institute, Boston, Massachusetts., Gao J; Memorial Sloan Kettering Cancer Center, New York, New York.; Caris Life Sciences, Irving, Texas., Schultz N; Memorial Sloan Kettering Cancer Center, New York, New York.
Jazyk:	angličtina
Zdroj:	Cancer research [Cancer Res] 2023 Dec 01; Vol. 83 (23), pp. 3861-3867.
DOI:	10.1158/0008-5472.CAN-23-0816
Abstrakt:	International cancer registries make real-world genomic and clinical data available, but their joint analysis remains a challenge. AACR Project GENIE, an international cancer registry collecting data from 19 cancer centers, makes data from >130,000 patients publicly available through the cBioPortal for Cancer Genomics (https://genie.cbioportal.org). For 25,000 patients, additional real-world longitudinal clinical data, including treatment and outcome data, are being collected by the AACR Project GENIE Biopharma Collaborative using the PRISSMM data curation model. Several thousand of these cases are now also available in cBioPortal. We have significantly enhanced the functionalities of cBioPortal to support the visualization and analysis of this rich clinico-genomic linked dataset, as well as datasets generated by other centers and consortia. Examples of these enhancements include (i) visualization of the longitudinal clinical and genomic data at the patient level, including timelines for diagnoses, treatments, and outcomes; (ii) the ability to select samples based on treatment status, facilitating a comparison of molecular and clinical attributes between samples before and after a specific treatment; and (iii) survival analysis estimates based on individual treatment regimens received. Together, these features provide cBioPortal users with a toolkit to interactively investigate complex clinico-genomic data to generate hypotheses and make discoveries about the impact of specific genomic variants on prognosis and therapeutic sensitivities in cancer. Significance: Enhanced cBioPortal features allow clinicians and researchers to effectively investigate longitudinal clinico-genomic data from patients with cancer, which will improve exploration of data from the AACR Project GENIE Biopharma Collaborative and similar datasets. (©2023 The Authors; Published by the American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu